Introduction
============

Nucleic acid amplification testing (NAT) in clinical specimens are increasingly used as a diagnostic tool in private clinical laboratories ([@b1-ijph-42-119]--[@b3-ijph-42-119]). These protocols are rapid and sensitive but needs to be standardized as a diagnostic method for patient's specimens ([@b4-ijph-42-119]--[@b5-ijph-42-119]). Therefore clinical validity remains controversial, until amplification tests to be proved reliable. At the present time laboratories are increasingly improving their instruments and space to apply molecular methods for diagnosis of bacterial, parasitic and especially viral agents that are highly claimed by the physicians ([@b6-ijph-42-119]--[@b7-ijph-42-119]). Molecular diagnostic methods are procedures that employing variety of technologies to help physician for better tailor patient treatments. A considerable number of these methods have been introduces to the clinical laboratory that needs to be standardized. Selecting a qualified instruments and running protocols at the diagnostic level are two most important facing problems especially in our country, because of their availability without any official permissions. These problems obviously cause on the sensitivity and specificity of the applied test ([@b8-ijph-42-119]). The most significant problems that must be solved before NATs to be become clinically useful; are false positive and false negative results ([@b9-ijph-42-119]).

Since introducing PCR, it has been developed and enhanced its quality of the performance the test for the clinical specimens. However, as a part of clinical service, a laboratory must maintain suitable quality in this area if accurate clinical information is to be provided to clinicians ([@b10-ijph-42-119]). Iran has a very widespread laboratory network. It is desired that this network, which has more than 4000 laboratories (public and private), achieve a certain level of quality, which is defined by national standards such as other country ([@b11-ijph-42-119]). This national reported standard has been based on the ISO 15189 and other specific issues regarding biosafety, management, external quality assessment, and so on ([@b12-ijph-42-119],[@b13-ijph-42-119]).

Applying standard guidelines for the space, instrumentation, and sampling, shipping specimens and molecular diagnostic protocols is necessary to have similar results in all laboratories. It seems we are not able to consider those international regulations such as ISO 15189 for clinical laboratory, because they applied before setting up the required regulations. At this stage, we need to provide national measurements before obligating of all international laboratory criteria. Therefore, an independent quality assurance program based on our situations is required to be established specifically by the Health Reference Laboratories for monitoring molecular tests assays performed by those medical laboratories.

Methods
=======

Development Quality Assurance program for the Molecular Methods
---------------------------------------------------------------

In view of the fact that there were no quality assurance program before ([@b13-ijph-42-119]), we have design specific program at first step based on the other country's experiments ([@b14-ijph-42-119]). In this program we have to firstly publish all necessary guidelines and checklist, considering training especially for selected auditors and then accreditation. Therefore, an independent quality assurance program has been established specifically by the Health Reference Laboratories for monitoring molecular tests assays performed by those medical laboratories.

Standard Guidelines
-------------------

Virology and Molecular Biology committee which established at 2008, in order to release some guidelines. The members of the committee participated in periodic benchmarking as a assessment of the laboratory performance in various provinces of Iran ([@b15-ijph-42-119]). They are going to be informed of applying running protocols and voluntary procedures or some probable deficiencies in the following provinces: Mazandaran, East Azarbayjan, Kermanshah, Sistan and Baluchestan, Kordestan, Gilan, Ghom, Fars, Esfahan, Kerman, Alborz and finally Tehran.

Training
--------

In this regards various workshops were designed and held for all those auditors who introduced by Laboratory Affairs Offices of each province through the country, focusing in Tehran at first step. We considered some circumstances for this group such as having enough knowledge and experience in molecular methods, as well as no engaging with any molecular companies, and having reasonable attitude and habit.

Checklist
---------

The next essential step was documenting an approved checklist in the field of molecular diagnosis tests. This check list had been prepared based on the released protocols. It was gradually modified in periodically benchmarking in some of provinces and finally was confirmed all modification and approved in the molecular biology committee. This checklist contained eighty one necessary questions on following items: personnel eligibility, bio-safety conditions, instruments qualifications, pre-analytical- analytical- and post-analytical processes, reporting sheet, and documentation of the results, storage conditions, quality of receiving and sending specimens, internal quality control program and finding error guidelines.

Accreditation program
---------------------

It was decided to select 50 laboratories with the highest receiving samples per day in Tehran at the first accreditation program. Prepared checklist was sent to all engaged laboratories with molecular tests to have self evaluation before attending our auditors at laboratories for molecular accreditation.

Results
=======

Issued Protocols
----------------

Following guidelines were issued by the Virology and Molecular Biology Committee after several nonstop working ([@b13-ijph-42-119]): Diagnostic molecular laboratory (especially for laboratory buildings and equipments), February 2008.Implementation of bio-safety program in molecular laboratories based on ISO15190 and other references, January 2008.Sampling, transportation and storage, July 2009.Nucleic Acid extraction from pathogenic agents, summer 2009. **- Training:** various workshops were held for the following groups: medical laboratories staffs, quality control officers of molecular companies, medical laboratory directors, directors and nominees from universities. Another workshop was also held regarding auditing.**- Molecular Companies Approving Process:** All active companies in the fields of molecular providing materials must be accredited as well as molecular section of medical laboratories. All molecular companies are accredited by ISO13485.There are some accredited EQA providers based on ISO17043 who has not been prepared to be activated in molecular field yet. These companies asked to improve their condition under surveillance of Medical Equipments Office under the observation of Laboratory Technology Management Office of Health Reference Laboratory. All these companies are asked to be registered themselves and either those producing materials and kits or those who import from other abroad corporations in order to evaluate the quality of their molecular products. Considered registration process is as follows:Complete the necessary forms regarding the activity fieldsIntroducing quality control officerConfirmation of standard process of product or entrance and storage regulations

All those companies who are going to import material marked as "research use only" are not allowed to sell their materials and kits to the clinical laboratories. All provided materials are also classified according to their risk group. They are also asked to announce their Notified Body in abroad. Some materials may be sent to reference laboratory for evaluation their qualities after checking their documents. The products of all those qualified firms by Medical Equipments Office, are being introduced to the Medical Laboratories as a confirmed available products. At the present time 39 Iranian companies have been applied for registration that 30 ones have completed their process. Some products of just 8 companies have been qualified for importing.

Auditing of the clinical Laboratories
-------------------------------------

At this stage it has been decided to focus firstly on selected medical laboratory of Tehran since these laboratories are engaging with most other laboratories even from all provinces of Iran. Based on the bench marking experiment specially the analysis of Tehran that was the largest one ([Table 1](#t1-ijph-42-119){ref-type="table"}), we decided to have a pre-evaluation before any auditing.

Therefore a questionnaire was prepared and sent to the all laboratories regarding general question regarding the laboratories, current space and instruments, applied diagnostic protocols, quality assurance and control, and finally reporting. All collected information was analyzed ([Table 2](#t2-ijph-42-119){ref-type="table"}--[5](#t5-ijph-42-119){ref-type="table"}). The analysis results of the clinical laboratories at Tehran benchmarking are presents in table number one.

Discussion
==========

The primary goal of Laboratory Medicine is to provide information that is useful to assist medical decision-making, allowing optimal health care. Molecular testing is expanding rapidly in many areas, particularly in microbiology and virology within the current space in Iran's medical laboratories. Clinical validation of the correctly calibrated routine conditions of molecular methods will take place, as soon as a reference measurement system is introduced and applied ([@b16-ijph-42-119],[@b17-ijph-42-119]) In this regards we requires a clear definition of the clinically justifiable error of measurements and validation criteria for analytical performance ([@b18-ijph-42-119]). Therefore, performance and applying standardization is required for improvement of results in Laboratory Medicine. Analysis of the questionnaire revealed all laboratories believed have collected all necessary instruments while bench marking showed only 23% of the laboratories had provided all required equipments. Documentations, and quality control policy also showed high differences between analyzed questionnaire and Tehran bench marking's results. It means in the auditing this item must be carefully evaluated ([Table 1](#t1-ijph-42-119){ref-type="table"}, [2](#t2-ijph-42-119){ref-type="table"}, and [4](#t4-ijph-42-119){ref-type="table"}). Issued molecular guidelines with essential and minimal conditions and also approved checklist were the primarily goals at this stage. In order to achieve this standardization a confirmed approach is then needed, including approved space and instruments, appropriated reference procedures and materials, having required quality control program, applying confirmed molecular materials and kits as well as training. Regarding the minimal required standard space conditions, separation of pre-amplification area from post-amplification necessitated in this diagnostic field. Separation of positive and negative air pressure can help the staff for the applied policy and it allows them to use generic instrumentation for multiple assays efficiently. Another point is applied conditions for sample preparation area, because of sample-to-sample contamination especially in those laboratories with large preparation rate. A dedicated space must be in a format to allow the laboratory for contamination control. Besides the required standard space and approved materials and equipments our major challenge is applied quality control program of the running diagnostic tests and documentations, since all of them must be considered for validity and the reliability of the molecular results ([@b19-ijph-42-119]). These two recent parameters will be improving by the active auditing. Therefore, issuing specific checklist and self auditing of each laboratory will ensure us of taken similar policy. We hope at the first stage of auditing to enhance quality of the applied materials, setting up the necessity documentation, and ensuring of taken plan for the reliability of the tests.

Designed Quality assurance for the medical molecular laboratories will be evaluated by the regular and active auditing.
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###### 

Analyzed data of Molecular Tehran Bench marking (%)

       **Inspected Items**                             **Frequency (%)**
  ---- ----------------------------------------------- -------------------
  1    Dedicated Space                                 61.5
  2    Provided Instruments                            23
  3    Storage conditions                              77
  4    Disposing the Swage                             93
  5    Extraction Procedures                           83
  6    SOPs for instruments                            33
  7    SOPs for protocols                              77
  8    Considered Correction Policies                  30.7
  9    Quality Control                                 7.7
  10   Documentations of the tests                     7.7
  11   Documentations of Quality Control Experiments   7.7

###### 

Standardization of space and instruments according to guideline 1

      **Asked question and subject**       **Frequency (%)**
  --- ------------------------------------ -------------------
  1   Current provided space               94
  2   Applied necessary instruments        100
  3   Documentations                       100
  4   Disposing the waste                  100
  5   Provided required bio-safety level   100

###### 

Applied protocols for molecular diagnosis

      **Asked question and subject**                     **Frequency (%)**
  --- -------------------------------------------------- -------------------
  1   Applied imported extraction kits                   76
  2   Availability of alternative extraction protocols   84
  3   Applied approved diagnostic protocols              64
  4   Availability of alternative diagnostic protocols   87.5
  5   Applied internal Control                           100
  6   Having policy use of CE-IVD, FDA                   100

###### 

Quality Assurance program

      **Asked question and subject**                                   **Frequency (%)**
  --- ---------------------------------------------------------------- -------------------
  1   Quality control of applied material before use                   83
  2   Use of reference materials                                       91
  3   Use of independent freezer for molecular tests                   91
  4   Regular calibration of instruments                               100
  5   Regular calibration of termocyclers                              96
  6   Regular calibration of micropipette                              100
  7   Policy of confirmation results                                   
      Repeating the test on the original                               32
      specimens                                                        29
      Repeating the test on the new                                    13
      specimens                                                        13
      Repeating the test with alternative protocols                    
      Sending to other laboratory                                      
  8   Intending to participate in external quality assurance program   95

###### 

Required parameters on the reporting sheet

      **Asked question and subject**                             **Frequency (%)**
  --- ---------------------------------------------------------- -------------------
  1   Mention required parameters on the reporting sheet         33
      Sensitivity                                                21.5
      Specificity                                                18.5
      Detection Limit                                            
  2   Specifying home brew protocol if using                     13
  3   Mention approved the diagnostic kit in the case of using   45
  4   Keeping all necessary documentation of patient's tests     100
